MDM2 and non-small cell lung carcinoma: However, our results show that other types of cancer, like NSCLC, could also benefit from MDM2-inhibitor combination strategies independent of the MDM2 expression status, by enhancing the expression and activation of wild type p53 in response to CDDP treatment.